Zobrazeno 51 - 60
of 236
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorenzo Spaggiari, Filippo de Marinis, Patrick Maisonneuve, Monica Casiraghi, Gaia Piperno, Piergiorgio Solli, Domenico Galetta, Daniela Brambilla, Francesco Petrella
Publikováno v:
European Journal of Cardio-Thoracic Surgery. 52:975-981
Objectives While the best approach to malignant pleural mesothelioma has yet to be demonstrated, surgery remains the mainstay of treatment. We analysed a group of candidates for trimodality treatment, aiming to identify prognostic factors guiding pat
Autor:
Domenico Amoroso, Alessandro Bertolini, Maria Rita Migliorino, Andrea Luciani, Adolfo Favaretto, Alba A. Brandes, Paolo Bidoli, Giuseppe Tonini, Cesare Gridelli, Filippo de Marinis
Publikováno v:
Anticancer Research. 37:2457-2464
Background/aim The management of elderly patients with advanced non-squamous NSCLC includes several strategies. Patients and methods Patients (≥70 years) were randomly assigned to bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2
Autor:
Giacomo Cartenì, Filippo de Marinis, Flavia Longo, Gianpiero Fasola, Domenico Galetta, Alberto Caprioli, Dario Giuffrida, Alberto Zaniboni, Valentina Acciai, Oscar Alabiso, Maria Rita Migliorino, Antonio Santo, Antonio Pazzola, Diego Cortinovis, Giampiero Romano, Sabrina Vari
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 143:783-791
Non-small cell lung cancer (NSCLC) is a condition with significant clinical burden for patients and relevant economic impact. Limited evidence exists on the management costs of NSCLC patients, especially in the late phases of the disease. The main ob
Autor:
Paolo Maione, Antonio Rossi, Antonio Chella, G. Valmadre, Maria Rita Migliorino, Paolo Bidoli, Serena Ricciardi, Matteo Brighenti, Cesare Gridelli, Giacomo Allegrini, Filippo de Marinis
Publikováno v:
Anticancer Research. 36:6535-6540
Background/Aim: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of e
Autor:
Gianluca Spitaleri, Filippo de Marinis, Niki Karachaliou, Chiara Catania, Antonio Passaro, Chiara Lazzari, Alessia Pochesci, Rafael Rosell
Publikováno v:
OncoTargets and therapy
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung can
Autor:
Cristina Noberasco, Laura Lavinia Travaini, Chiara Catania, Antonio Passaro, Filippo de Marinis, Gianluca Spitaleri, Elena Guerini Rocco, Ester Del Signore, Massimo Barberis
Publikováno v:
Clinical Lung Cancer. 17:e179-e183
HER2 mutations are uncommon molecular mutations in nonesmall-cell lung cancer (NSCLC) (4%). Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC who harbor epidermal growth fa
Autor:
Antonio Rossi, Francesco Perrone, Filippo de Marinis, Fortunato Ciardiello, Agnese Montanino, Cesare Gridelli, Floriana Morgillo, Nicola Normanno, Ciro Gallo, Gennaro Daniele, Lucio Crinò, Maria Carmela Piccirillo, Alessandro Morabito
Publikováno v:
Clinical Lung Cancer. 17:461-465
BACKGROUND: About 20% of advanced non-small-cell lung cancer (NSCLC) cases harbor somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene. In these patients, the standard first-line treatments are the EGFR-
Autor:
Laura Pala, Emilia Cocorocchio, Filippo de Marinis, Vincenzo Bagnardi, Richard D. Gelber, Eleonora Pagan, Giuseppe Viale, Fabio Conforti, Aron Goldhirsch, Elisabetta Pennacchioli, Pier Francesco Ferrucci, Tommaso De Pas
Publikováno v:
J Natl Cancer Inst
BackgroundWe previously showed that therapy with anti–checkpoints T-lymphocyte-associated protein 4 (anti–CTLA-4) or antiprogrammed cell death protein 1 (anti–PD-1) agents was more effective for men as compared with women. However, because the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78f1a6af583e64a3ce837e04c6384ca
http://hdl.handle.net/10281/239378
http://hdl.handle.net/10281/239378
Autor:
Silvia Novello, Françoise Mornex, Rafal Dziadiuszko, Martin Früh, Enriqueta Felip, Federico Cappuzzo, Markus Glatzer, Corinne Faivre-Finn, Fiona H Blackhall, Ben J. Slotman, Mary O’ Brien, Dirk De Ruysscher, Esther G.C. Troost, Paul Van Houtte, Stéphanie Peeters, José Belderbos, Benjamin Besse, Sara Ramella, Fiona McDonald, Paul Martin Putora, Martin Reck, Pilar Garrido, Cécile Le Péchoux, Filippo de Marinis, Virginie Westeel, Ursula Nestle, Raffaele Califano, Joachim Widder, Christoph Pöttgen, L. Arés
Publikováno v:
Radiotherapy and Oncology, 135, 74-77. Elsevier Ireland Ltd
Radiotherapy and Oncology 135(2019), 74-77
Putora, P M, Glatzer, M, de Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien, M O, Paz Ares, L, Peeters, S, Pöttgen, S, Ramella, S, Reck, M, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & Slotman, B J 2019, ' Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 135, pp. 74-77 . https://doi.org/10.1016/j.radonc.2019.02.010
Radiotherapy and Oncology 135(2019), 74-77
Putora, P M, Glatzer, M, de Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien, M O, Paz Ares, L, Peeters, S, Pöttgen, S, Ramella, S, Reck, M, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & Slotman, B J 2019, ' Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 135, pp. 74-77 . https://doi.org/10.1016/j.radonc.2019.02.010
Background: The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted.Methods: We obtained a list of 13 European medical oncologists from the International Association for the Study of L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9e8d893418515be78de97bf8a595780
http://hdl.handle.net/2318/1694881
http://hdl.handle.net/2318/1694881
Autor:
Francovito Piantedosi, Antonio Santo, Claudia Proto, Antonio Frassoldati, Angelo Delmonte, Filippo de Marinis, Libero Ciuffreda, Enrico Cortesi, Paolo Bidoli, Graziella Pinotti, Marco Bregni, Riccardo Samaritani, Federico Cappuzzo, Lucio Crinò, Alfonso Illiano, Paola Cravero, Elisa Minenza, Giuseppe Tonini, Diana Giannarelli, Gianmauro Numico, Stefano Tamberi, Maria Giuseppina Sarobba, Francesco Grossi, Marina Chiara Garassino, Giuseppe Bronte
Objectives Brain metastases are common among patients with non-squamous non-small-cell lung cancer (NSCLC) and result in a poor prognosis. Consequently, such patients are often excluded from clinical trials. In Italy an expanded access program (EAP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2794d1e913ffea6eef310029db4b7f07
http://hdl.handle.net/11573/1296150
http://hdl.handle.net/11573/1296150